INTRODUCTION
Solid cancers are heterocellular systems containing both tumor cells and stromal cells. Coercion of stromal cells by tumor cell oncogenes profoundly impacts cancer biology (Friedl and Alexander, 2011; Quail and Joyce, 2013) and aberrant tumor-stroma signaling regulates many hallmarks of cancer (Hanahan and Weinberg, 2011) . While individual oncogene-driven regulators of tumor-stroma signaling have been identified, the propagation of oncogene-dependent signals throughout a heterocellular system is poorly understood. Consequently, our perspective of oncogenic signaling is biased toward how oncogenes regulate tumor cells in isolation (Kolch et al., 2015) .
In a heterocellular cancer, tumor cell oncogenes drive aberrant signaling both within tumor cells (cell-autonomous signaling) and adjacent stromal cells (non-cell-autonomous signaling) (Croce, 2008; Egeblad et al., 2010) . As different cell types process signals via distinct pathways (Miller-Jensen et al., 2007) , heterocellular systems (containing different cell types) theoretically provide increased signal processing capacity over homocellular systems (containing a single cell type). By extension, oncogene-dependent signaling can theoretically engage additional signaling pathways in a heterocellular system when compared to a homocellular system. However, to what extent activated stromal cells reciprocally regulate tumor cells beyond cell-autonomous signaling is not well understood.
We hypothesized that the expanded signaling capacity provided by stromal heterocellularity allows oncogenes to establish a differential reciprocal signaling state in tumor cells. To test this hypothesis, we studied oncogenic KRAS (KRAS G12D ) signaling in pancreatic ductal adenocarcinoma (PDA). KRAS is one of the most frequently activated oncogenic drivers in cancer (Pylayeva-Gupta et al., 2011) and is mutated in >90% of PDA tumor cells (Almoguera et al., 1988) . PDA is an extremely heterocellular malignancy-composed of mutated tumor cells, stromal fibroblasts, endothelial cells, and immune cells (Neesse et al., 2011) . Crucially, the gross stromal pancreatic stellate cell (PSC) expansion observed in the PDA microenvironment is non-cell-autonomously controlled by tumor cell KRAS G12D in vivo (Collins et al., 2012; Ying et al., 2012) . As a result, understanding the heterocellular signaling consequences of KRAS G12D is essential to comprehend PDA tumor biology.
Comprehensive analysis of tumor-stroma signaling requires concurrent measurement of cell-specific phosphorylation events. Recent advances in proteome labeling now permit cellspecific phosphoproteome analysis in heterocellular systems (Gauthier et al., 2013; Tape et al., 2014a) . Furthermore, advances in proteomic multiplexing enable deep multivariate phosphosignaling analysis (McAlister et al., 2012; Tape et al., 2014b) .
Here, we combine cell-specific proteome labeling, multivariate phosphoproteomics, and inducible oncogenic mutations to describe KRAS G12D cell-autonomous, non-cell-autonomous, and reciprocal signaling across a heterocellular system. This study reveals KRAS G12D uniquely regulates tumor cells via heterotypic stromal cells. By exploiting heterocellularity, reciprocal signaling enables KRAS G12D to engage oncogenic signaling pathways beyond those regulated in a cell-autonomous manner. Expansion of KRAS G12D signaling via stromal reciprocation suggests oncogenic communication should be viewed as a heterocellular process.
RESULTS
Tumor Cell KRAS G12D Non-cell-autonomously Regulates
Stromal Cells
To investigate how KRAS G12D supports heterocellular communication, we first analyzed tumor cell-secreted signals (using PDA tumor cells containing an endogenous doxycycline inducible KRAS G12D ) (Collins et al., 2012; Ying et al., 2012) . Measuring 144 growth factors, cytokines, and receptors across three unique PDA isolations, we observed that KRAS G12D increased secretion of GM-CSF, GCSF cytokines, and the growth morphogen sonic hedgehog (SHH) ( Figure 1A ). As SHH regulates pancreatic myofibroblast expansion (Collins et al., 2012; Fendrich et al., 2011; Thayer et al., 2003; Tian et al., 2009; Yauch et al., 2008) , and ablation of SHH signaling reduces PDA tumor stroma in vivo (Lee et al., 2014; Olive et al., 2009; Rhim et al., 2014) , we focused on understanding the trans-cellular signaling consequences of SHH. As previously established, KRAS G12D simultaneously induces SHH secretion (Collins et al., 2012; Lauth et al., 2010) (Figure 1B ) and disrupts primary cilium in PDA cells ( Figure 1C ). Concordantly, PSCs and KRAS WT PDA cells transduce canonical SHH signaling (via SMO-GLI), while KRAS G12D cells do not ( Figure 1D ).
This enables KRAS G12D PDA cells to non-cell-autonomously signal to PSCs via SHH, while remaining insensitive to autocrine SHH ( Figure 1E ). Quantitative proteomic analysis revealed SHH induces widespread changes across the cytoplasmic, membrane, and secreted PSC proteome (Figures 1F, 1G, and S1A; Data S1 achieves a unique signaling output (e.g., production of ECM, IGF1, and GAS6) via stromal cells that is distinct from that produced by tumor cell KRAS G12D alone.
KRAS G12D Regulates Distinct Cell-Autonomous Signaling
To provide a baseline of cell-autonomous oncogene-regulated signaling from which to compare stromal-dependent reciprocal signaling, we first determined the effect of KRAS G12D expression on the PDA phosphoproteome (Figures 2A, 2B , and S2A). Despite being the primary oncogenic driver in PDA, KRAS
G12D
only regulates 7% of the observed tumor cell phosphoproteome (+/À1 log 2 , p < 0.01) ( Figure 2C ; Data S1). KRAS G12D expression induces canonical activation of ERK1/2 and increases phosphorylation of MAPK/CDK1/CKII-directed kinase motifs. However, while the PI3K-AKT axis is often presumed directly downstream of KRAS G12D in PDA (Eser et al., 2014 )-expression of KRAS G12D does not activate AKT in a cell-autonomous manner ( Figures 2D and S2 ). This observation is consistent across multiple PDA cell isolations from several independently developed genetic mouse models (Collins et al., 2012; Ying et al., 2012) ( Figure S3 Figure 2E ; Data S1).
Collectively Figures  S4C-S4E ). Targeted temporal analysis revealed SHH-activated PSCs induce rapid phosphorylation of IGF1R (receptor for IGF-1), AXL/TYRO3 (receptor for GAS6), and downstream IRS-1 and AKT (pT308/pS473) in KRAS G12D PDA cells ( Figure 3D ). Tumor cells treated with conditioned media from control or SHH-activated PSCs and perturbed with either MEK and/or AKT inhibitors further confirmed PSCs drive a differential phosphoproteome in PDA cells. However, unlike cell-autonomous KRAS G12D , stromal-driven signaling depends on both active MEK and AKT ( Figure 3E ; Data S1).
As IGF1 and GAS6 are secreted by activated PSCs, we investigated the dependency of IGF1R and AXL activity on the PSC-induced tumor cell phosphoproteome. Combined IGF1R and AXL inhibitors are required to block the PSC-induced tumor cell phosphoproteome-suggesting a Boolean ''OR'' axis between PSC IGF1/GAS6 and PDA pAKT ( Figures 3F, 3G , and S4F; Data S1).
Collectively, these results reveal activated stromal cells can return a differential signal to tumor cells via an IGF1R/AXL-AKT axis. The stromal-driven tumor cell phosphoproteome is distinct from the KRAS G12D regulated cell-autonomous phosphoproteome and responds differently to pharmacological perturbation.
KRAS G12D Regulates Tumor Cell Signaling via a Reciprocal Signaling Axis
Our data suggests that oncogenic KRAS in tumor cells establishes a reciprocal signaling axis between stromal cells and tumor cells. Herein, we define an oncogenic reciprocal signaling axis as an oncogenic cue that signals via an adjacent heterotypic See also Figure S1 and Data S1.
cell to produce a distinct response in the oncogene-expressing cell. For this heterocellular variation on the ''cue-signalresponse'' systems biology paradigm (Janes et al., 2004 (Janes et al., , 2005 Miller-Jensen et al., 2007) to be valid, we hypothesized that oncogenic reciprocal signaling requires three essential features:
(1) an oncogenic cue (e.g., KRAS G12D ), (2) a cue-driven non-cellautonomous signal (e.g., KRAS G12D -induced SHH), and (3) a heterotypic cell capable of transducing the signal response back to the instigating oncogenic cell (e.g., PSC). To test this multi-node reciprocal signaling hypothesis, we systematically perturbed each reciprocal feature in a native heterocellular tumor-stroma context.
To measure multivariate signaling in a heterocellular system, concurrent cell-specific and variable-specific phosphoproteomic data are required. We have previously shown that stable isotopic proteome labeling (Ong et al., 2002) can resolve between discrete cell types in direct culture of heterotypic cells (Jorgensen et al., 2009 ) and recently introduced cell type-specific labeling with amino acid precursors (CTAP) (Gauthier et al., 2013 ) Lyr M37-KDEL and DDC M.tub-KDEL enzymes for cell-specific isotopic labeling (Tape et al., 2014a) . To this end, we combined CTAP labeling (spatial resolution) with isobaric tandem mass tag (TMT) phosphoproteomics (variable resolution) (Tape et al., 2014b; Thompson et al., 2003) to enable heterocellular multivariate phosphoproteomic analysis of each reciprocal signaling component ( Figure 4A ). This technique allows simultaneous observation of cell-autonomous, non-cell-autonomous, and reciprocal oncogenic phosphoproteomes at cell-specific resolution.
Cell-specific phosphoproteomes were interrogated in PDA cells expressing either KRAS WT or KRAS G12D , either in homoor heteroculture with isotopically ''heavy''-labeled PSCs, and treated with either SHH inhibitor or vehicle. We monitored 3,695 lysine-containing (8,566 total) phosphopeptides across eight conditions, two heterotypic cell types, and three biological replicates with cell-specific resolution (Figures 4B and S5; Data S1). As expected, expression of KRAS G12D in tumor cells alone regulates (+/À1 log 2 ) 7.2% of the identified cell-autonomous phosphoproteome. In parallel, tumor cell KRAS G12D noncell-autonomously regulates 4.7% of the PSC phosphoproteome. Moreover, when KRAS G12D is allowed to communicate with PSCs via SHH, a reciprocal axis is completed and the differentially regulated tumor cell phosphoproteome almost doubles to 13.8%. Importantly, perturbation by a SHH blocking antibody decreases the phosphoproteomic regulation on PSCs back down to 1.2% and PDA phosphoproteome to 8.1% (close to cell-autonomous at 7.2%).
Heterocellular multivariate phosphoproteomics demonstrates how tumor cell oncogenes exploit the differential signaling capacity of stromal cells to achieve a unique signaling state in the inceptive tumor cell. KRAS G12D reciprocal signaling engages additional phospho-nodes to cell-autonomous KRAS G12D alone, allowing KRAS G12D to extend the oncogenic signaling capacity in the inceptive tumor cells. Crucially, these observations are the product of native tumor-stroma signaling and are independent of exogenous stimulation. by engaging additional tumor cell kinases ( Figure S6B ). (Figures S6C-S6F) , further suggesting a de novo control of PDA protein abundance. To validate whether the SHH-driven reciprocal signaling axis regulates de novo tumor cell protein turnover, PSC+DDC M.tub-KDEL and PDA+Lyr M37-KDEL CTAP cells were differentially isotopically labeled, treated with a SHH inhibitor or vehicle, and cell-specific proteomes were quantified in heteroculture ( Figure 5D ). This experimental format permitted cell-specific quantification of changes to the KRAS G12D tumor cell proteome following inhibition of the PSC targeting signal (SHH). Parallel perturbations with AKT and IGF1R/AXL inhibitors provided additional insight into the role of each reciprocal node. Cell-specific proteomics confirmed KRAS G12D reciprocally regulates the PDA proteome and is dependent on active SHH, IGF1R/AXL, and AKT signaling ( Figure 5E ; Data S1). As with the PDA phosphoproteome, reciprocal signaling regulates the PDA proteome differently to cell-autonomous KRAS
G12D
. For example, while cell-autonomous KRAS G12D rapidly depletes distinct mitochondrial components from PDA cells (Data S1) (Viale et al., 2014), reciprocally engaged KRAS G12D restores mitochondrial proteins in an SHH-, IGF1R/AXL-, and AKT-dependent manner. Moreover, PDA proteins involved with DNA replication are also upregulated under reciprocal conditions. These results demonstrate reciprocal signaling uniquely regulates both the tumor cell phosphoproteome and global proteome when compared to cell-autonomous signaling. Reciprocal signaling states are unique to a heterocellular environment and are not observed in tumor cells alone.
KRAS
G12D -Driven Reciprocal Signaling Regulates Tumor Cell Phenotypes Reciprocal signaling regulates proteins and phospho-sites known to control several important biological processes. For example, while cell-autonomous and reciprocal KRAS G12D signaling both regulate mitochondrial proteins, many of these are asymmetrically regulated. As a result, we hypothesized PDA mitochondrial activity would be differentially regulated by cell-autonomous and reciprocal KRAS G12D . Concordantly, cell-autonomous KRAS G12D decreases PDA mitochondria polarization (Dc m ) and mitochondrial superoxide production, whereas reciprocal signaling increases these processes (via SHH, IGF1R/ AXL, and AKT) ( Figures 6A and S7) . Furthermore, reciprocal Figure S4 and Data S1.
signaling increases spare mitochondrial respiratory capacity in tumor cells ( Figure 6B ). These results demonstrate KRAS G12D can differentially regulate mitochondrial performance via heterocellular communication.
Reciprocal signaling also regulates proteins known to control cell proliferation and survival. In agreement, cell-specific analysis of PDA proliferation in homo and heterocellular cultures revealed increased tumor cell proliferation under heterocellular conditions (via SHH, IGF1R/AXL, and AKT activity) ( Figure 6C ). Upregulation of AKT substrates (e.g., inhibition of BAD [pS136]) also suggested reciprocal signaling might protect tumor cells from apoptosis. Concordantly, TUNEL and caspase 3/7 profiling revealed activated PSCs protect tumor cells from apoptosis and sensitize tumor cells to reciprocal node inhibitors (IGF1R/AXL and AKT) (Figures 6D-6E) .
Increased mitochondrial performance, proliferative capacity, and resistance to apoptosis collectively implied reciprocal signaling supports tumor cell phenotypes beyond cell-autonomous KRAS G12D . In accordance, reciprocal signaling increases semi-solid colony growth relative to cell-autonomous KRAS G12D alone ( Figure 6F ). Reciprocal colony growth is dependent on SHH activation of PSCs and IGF1R/AXL-AKT activity in tumor cells.
Collectively, these results demonstrate the unique signals produced by reciprocal KRAS G12D control distinct metabolic, proliferative, anti-apoptotic, and anchorage-independent growth phenotypes in tumor cells.
DISCUSSION
Whether oncogenes regulate tumor cell signaling via stromal cells is a fundamental question in tumor biology. Using heterocellular multivariate phosphoproteomics, we demonstrate how oncogenic KRAS signals through local non-tumor cells to achieve a differential reciprocal signaling state in the inceptive tumor cells. In PDA, this reciprocal axis supplements oncogenic cell-autonomous signaling to control protein abundance, transcription, mitochondrial activity, proliferation, apoptosis, and colony formation. Reciprocal signaling is the exclusive product of heterocellularity and cannot be achieved by tumor cells alone. These observations imply oncogenes expand their capacity to deregulate cellular signaling via stromal heterocellularity (Figure 7 ). Despite the well-established heterocellularity of cancer, our understanding of oncogenic signaling within tumor cells has largely excluded non-tumor cells. We observe that stromal cells approximately double the number of tumor cell signaling nodes regulated by oncogenic KRAS, suggesting both cell-autonomous (internal) and reciprocal (external) stimuli should be considered when defining aberrant oncogenic signaling states. For example, although KRAS is thought to cell-autonomously regulate AKT in PDA (Eser et al., 2014) , we show that KRAS G12D activates AKT, not cell-autonomously, but reciprocally. As PI3K signaling is essential for PDA formation in vivo (Baer et al., 2014; Eser et al., 2013; Wu et al., 2014) reciprocal signaling may control oncogene-dependent tumorigenesis. Our findings suggest future genetic studies should consider the heterocellular signaling consequences of oncogene/tumor-suppressor deregulation.
The observation that many oncogene-dependent tumor cell signaling nodes require reciprocal activation has important implications for identifying pharmacological inhibitors of oncogene signaling. For example, if PDA tumor cells were screened alone, one would expect MEK, MAPK, and CDK inhibitors to perturb KRAS G12D signaling. However, when screened in conjunction with heterotypic stromal cells, our study additionally identified SHH, AKT, and IGF1R/AXL inhibitors as KRAS G12D -dependent See also Figure S6 and Data S1.
toward the non-oxidative pentose phosphate pathway (Ying et al., 2012) , whereas KRAS G12D -ablated cells depend on mitochondrial activity (Viale et al., 2014) . Here, we show that heterocellular reciprocal signaling can restore the expression of mitochondrial proteins and subsequently re-establish both mitochondrial polarity and superoxide levels. This suggests KRAS G12D regulates nonoxidative flux through cell-autonomous signaling and mitochondrial oxidative phosphorylation through reciprocal signaling. These results provide a unique example of context-dependent metabolic control by oncogenes and reinforce the emerging role of tumor-stroma communication in regulating cancer metabolism (Ghesquiè re et al., 2014) . In PDA, the stroma has dichotomous pro-tumor (Kraman et al., 2010; Sherman et al., 2014) and anti-tumor (Lee et al., 2014; Rhim et al., 2014) properties. It is becoming increasingly evident that non-cell-autonomously activated stromal cells vary within a tumor and can influence tumors in a non-obvious manner. For example, while vitamin D receptor normalization of stromal fibroblasts improves PDA therapeutic response (Sherman et al., 2014) , total stromal ablation increases malignant behavior (Lee et al., 2014; Rhim et al., 2014) . Thus, while stromal purging is unlikely to provide therapeutic benefit in PDA, ''stromal reprogramming'' toward an anti-tumor stroma is now desirable (Brock et al., 2015) . Although we describe a largely pro-tumor reciprocal axis, both pro-and anti-tumor stromal phenotypes likely transduce across reciprocal signaling networks. Our work suggests future efforts to therapeutically reprogram the PDA stroma toward anti-tumor phenotypes will require an understanding of reciprocal signaling. In describing the first oncogenic reciprocal axis, this study provides a foundation to measure the cell-cell communication required for anti-tumor stromal reprogramming. . Inhibiting IGF1R/AXL or AKT increases apoptosis when reciprocal signaling is active (n = 9). *p < 0.05, **p < 0.01, ***p < 0.001. (E) Caspase 3/7 activity in (D) (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001. (F) Semi-solid PDA colony formation. Reciprocal signals increase colony formation (via SHH, IGF1R/AXL, and AKT) relative to cell-autonomous KRAS G12D alone (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S7 .
We demonstrate heterocellular multivariate phosphoproteomics can be used to observe reciprocal signaling in vitro. Unfortunately, cell-specific isotopic phosphoproteomics is not currently possible in vivo. To delineate reciprocal signaling in vivo, experimental systems must support manipulation of multiple cell-specific variables and provide cell-specific signaling readouts. Simple pharmacological perturbation of reciprocal nodes (e.g., IGF1R, AXL, AKT, etc.) in existing PDA GEMMs will in principle affect all cell types (e.g., tumor cells, PSCs, immune cells) and cannot provide axis-specific information in vivo. Future in vivo studies of reciprocal signaling will require parallel inducible genetic manipulation (e.g., oncogene activation in cancer cell and/or inhibition of reciprocal node in stromal cell), combined with cell-specific signaling data (e.g., using epithelial tissue mass-cytometry) (Simmons et al., 2015) .
We describe KRAS G12D reciprocal signaling between PDA tumor cells and PSCs. However, it is likely oncogenic reciprocal signaling occurs across multiple different cell types in the tumor microenvironment. For example, in PDA, FAP + stromal fibroblasts secrete SDF1 that binds tumor cells to suppress T cells (Feig et al., 2013) . Our model predicts oncogene signaling expands across several cell types in the tumor microenvironment-including immune cells. Moreover, as oncogenes noncell-autonomously regulate the stroma in many other tumor types (Croce, 2008) , our model predicts oncogenic reciprocal signaling to be a broad phenomenon across all heterocellular cancers. The presented heterocellular multivariate phosphoproteomic workflow now enables future characterization of oncogenic reciprocal signaling in alternative cancer types. As differentiated cells process signals in unique ways, heterocellularity provides increased signal processing space over homocellularity. We provide evidence that KRAS G12D exploits heterocellularity via reciprocal signaling to expand tumor cell signaling space beyond cell-autonomous pathways. Given the frequent heterocellularity of solid tumors, we suspect reciprocal signaling to be a common-albeit under-studied-axis in oncogene-dependent signal transduction.
EXPERIMENTAL PROCEDURES KRAS

G12D
-Induced Soluble Signaling Molecules KRAS WT PDA cells (1 3 10 6 ) were plated in a 6-well dish and cultured in DMEM + 0.5% FBS ± 1 mg/ml doxycycline for 72 hr. Conditioned media was analyzed for relative changes in KRAS
-driven cytokines and growth factors using the RayBio Mouse Cytokine Antibody Array G2000 (RayBiotech AAM-CYT-G2000-8) (144 proteins quantified in duplicate per sample). SHH-N expression after 24 hr was further validated by sandwich ELISA (R&D Systems DY461).
KRAS G12D Cell-Autonomous Signaling
For comprehensive phosphoproteomic quantification of KRAS
G12D
-dependent cell-autonomous signaling, 1 3 10 6 KRAS WT PDA cells were plated in a 6-well dish (DMEM + 0.5% FBS) and cultured ± 1 mg/ml doxycycline for 24 hr (biological replicates n = 5). Cells were lysed in 6 M urea, 10 mM NaPPi, 20 mM HEPES, pH 8.0, sonicated, centrifuged to clear cell debris, and protein concentration was determined by BCA (Pierce 23225). One hundred micrograms of each condition were individually digested by FASP (Wi sniewski et al., 2009 ), amine-TMT-10-plex-labeled (Pierce 90111) on membrane (iFASP) (McDowell et al., 2013) , eluted, pooled, lyophilized, and subjected to automated phosphopeptide enrichment (APE) (Tape et al., 2014b) . Phosphopeptides were desalted using OLIGO R3 resin (Life Technologies 1-1339-03) and lyophilized prior to liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis (see the Supplemental Experimental Procedures).
Automated Phosphopeptide Enrichment
For TMT-labeled samples, phosphopeptides were enriched from each fraction using the automated phosphopeptide enrichment (APE) method described by Tape et al. (2014b) . Phosphopeptide fractions were individually desalted using OLIGO R3 resin (Life Technologies 1-1339-03) and resuspended in 0.1% formic acid prior to Q-Exactive Plus HCD FT/FT LC-MS/MS (see the Supplemental Experimental Procedures). For reciprocal phosphoproteomics PSC-PDA co-cultures, 15 mg protein was digested with 150 mg Lys-C (Wako 125-05061) (24 hr) and 150 mg Trypsin (Worthington) (24 hr) using 2 ml FASP. Lyophilized tryptic peptides were re-suspended in 60% MeCN and resolved using a Ultimate 3000 (Dionex) high-performance liquid chromatography fitted with a 10 mm particle size, 7.8 mm ID, and 30 cm TSKgel Amide-80 hydrophilic interaction liquid chromatography ( 
Multi-axis Phosphoproteomics
For concurrent PDA cell-autonomous and reciprocal phosphoproteomics, 1 3 10 6 PSCs were plated in a 6-well dish, stimulated with 5 nM SHH-N (C25II) (R&D Systems 464-SH-025/CF) in DMEM + 0.5% FBS, and conditioned media was collected after 48 hr. PDA cells (1 3 10 6 ) were cultured without doxycycline (KRAS WT ), with 1 mg/ml doxycycline (KRAS G12D ), and with 1 mg/ml doxycycline (KRAS G12D ) + PSC+SHH conditioned media (biological n = 3) (all in +0.5% dialyzed FBS). One hundred micrograms of each condition was then processed for TMT and APE analysis as described above. 3, 4, 4, 5, 5, 6, . PDA+DDC cells (3 3 10 6 ) were cultured in a 10 cm dish ± 1 mg/ml doxycycline, ±10 mg/ml SHH neutralizing monoclonal antibody (mAb) (R&D Systems MAB4641) and ±3 3 10 6 ''Heavy'' PSC+Lyr cells (biological triplicates). All cells were grown in DMEM (-K/-R) supplemented with 0.5% (v/v) dialyzed FBS, 0.3 mM L-arginine, 5 mM DAP, and 2.5 mM ''Heavy'' D-lysine. After 5 days, each condition was lysed in 6 M urea, sonicated, centrifuged to clear cell debris, and protein concentration was determined by BCA. One hundred micrograms of each variable was then processed for TMT and APE analysis as described above.
Cell-Type Labeling with Amino Acid Precursors
Heterocellular Reciprocal Proteomics
To investigate reciprocal regulation of PDA protein abundance, ''Heavy'' PDA+ Lyr M37-KDEL cells were co-cultured with ''Light'' PSC+DDC M.tub-KDEL in the presence of 2.5 mM ''Heavy'' D-lysine-3,3,4,4,5,5,6,6-d8 and 5 mM ''Light'' DAP (biological n = 3). For each experiment, a control co-culture of ''Medium'' PDA+ Lyr M37-KDEL cells and ''Light'' PSC+DDC M.tub-KDEL was performed in the presence of either PDA pre-treatment with IGF1R inhibitor (250 nM picropodophyllin [PPP]), AXL inhibitor (500 nM R428), or 20 mg/ml SHH-neutralizing antibody (R&D Systems MAB4641). All co-cultures were performed in +0.5% dialyzed FBS for 72 hr. Co-cultures were lysed in 100 mM Na 2 CO 3 (pH 11.0), pooled, snap-frozen in liquid nitrogen, treated with Benzonase (Novagen 70746), centrifuged at 40,000 rpm (to resolve membrane-bound proteins from cytosolic proteins), and denatured in 6 M urea 2 M thiourea. Differential changes in cytoplasmic and membrane protein levels were determined using ''In-gel digestion'' (see the Supplemental Experimental Procedures). To investigate the comparative KRAS G12D cell-autonomous proteome, KRAS WT ''Medium'' and ''Heavy'' PDA+Lyr M37-KDEL cells were seeded into 10-cm dishes (biological n = 3) (5 3 10 6 PDA cells/plate). Doxycycline (1 mg/ml) was then added to the ''Heavy'' PDA cells (i.e., KRAS
G12D
) and the ''Medium'' cells were left untreated (i.e., KRAS WT ) (in +0.5% dialyzed FBS). After 72 hr, cells were lysed as above.
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